Literature DB >> 28461313

Phenotypic and Molecular Evaluation of Echinocandin Susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis Strains Isolated during 30 Years in Argentina.

Soraya Morales-López1, Catiana Dudiuk2,3, Walter Vivot1, Wanda Szusz1, Susana B Córdoba1, Guillermo Garcia-Effron4,3.   

Abstract

The echinocandin susceptibilities of 122 Candida glabrata complex strains (including 5 Candida nivariensis and 3 Candida bracarensis strains) were evaluated by microdilution and compared with the results from a molecular tool able to detect FKS mutations. No echinocandin resistance was detected. The PCR results coincide with the MIC data in 99.25% of the cases (1 C. glabrata strain was misidentified as resistant) but were 20 h faster. C. nivariensis FKS genes were sequenced and showed differences with C. glabrataFKS genes.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida bracarensis; Candida glabrata species complex; Candida nivariensis; echinocandin resistance; hot spot

Mesh：

Substances：

Year:  2017        PMID： 28461313      PMCID： PMC5487631          DOI： 10.1128/AAC.00170-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus.

Authors:  Julia Alcoba-Flórez; Sebastián Méndez-Alvarez; Josep Cano; Josep Guarro; Eduardo Pérez-Roth; María del Pilar Arévalo
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

Review 4.  Candida glabrata: a deadly companion?

Authors:  Monique Bolotin-Fukuhara; Cécile Fairhead
Journal:  Yeast       Date:  2014-06-13       Impact factor: 3.239

5.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

6.  Echinocandin Resistance in Candida.

Authors:  David S Perlin
Journal:  Clin Infect Dis       Date:  2015-12-01       Impact factor: 9.079

7.  Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance.

Authors:  Catiana Dudiuk; Soledad Gamarra; Florencia Leonardeli; Cristina Jimenez-Ortigosa; Roxana G Vitale; Javier Afeltra; David S Perlin; Guillermo Garcia-Effron
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

8.  Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance.

Authors:  Angela Ahlquist Cleveland; Lee H Harrison; Monica M Farley; Rosemary Hollick; Betsy Stein; Tom M Chiller; Shawn R Lockhart; Benjamin J Park
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

9.  Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program.

Authors:  André Mario Doi; Antonio Carlos Campos Pignatari; Michael B Edmond; Alexandre Rodrigues Marra; Luis Fernando Aranha Camargo; Ricardo Andreotti Siqueira; Vivian Pereira da Mota; Arnaldo Lopes Colombo
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

10.  First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes.

Authors:  Maria Helena Galdino Figueiredo-Carvalho; Livia de Souza Ramos; Leonardo Silva Barbedo; Alessandra Leal da Silva Chaves; Ilda Akemi Muramoto; André Luis Souza dos Santos; Rodrigo Almeida-Paes; Rosely Maria Zancopé-Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-01       Impact factor: 2.743
View more
  8 in total

1.  Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.

Authors:  Ainara Hernando-Ortiz; Estibaliz Mateo; Marcelo Ortega-Riveros; Iker De-la-Pinta; Guillermo Quindós; Elena Eraso
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  First report of Candida bracarensis in Mexico: hydrolytic enzymes and antifungal susceptibility pattern.

Authors:  Rogelio de J Treviño-Rangel; José F Espinosa-Pérez; Hiram Villanueva-Lozano; Alexandra M Montoya; Angel Andrade; Alexandro Bonifaz; Gloria M González
Journal:  Folia Microbiol (Praha)       Date:  2018-02-27       Impact factor: 2.099

3.  Candida glabrata complex from patients with healthcare-associated infections in Mansoura University Hospitals, Egypt: distribution, antifungal susceptibility and effect of fluconazole and polymyxin B combination.

Authors:  Ghada Mashaly; Raghdaa Shrief
Journal:  Germs       Date:  2019-09-02

4.  Lack of detection of Candida nivariensis and Candida bracarensis among 440 clinical Candida glabrata sensu lato isolates in Kuwait.

Authors:  Mohammad Asadzadeh; Ahlam F Alanazi; Suhail Ahmad; Noura Al-Sweih; Ziauddin Khan
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

5.  Prevalence and Antifungal Susceptibility of the Emerging Fungal Species, Candida nivariensis, Isolated in a Teaching Hospital in Poland.

Authors:  Magdalena Sikora; Robert Kuthan; Katarzyna Piskorska-Malolepsza; Marlena Golas-Pradzynska; Dariusz Domański; Ewa Augustynowicz-Kopeć; Ewa Swoboda-Kopec
Journal:  Pol J Microbiol       Date:  2019-09-03

6.  Rapid identification of the Candida glabrata species complex by high-resolution melting curve analysis.

Authors:  Shuqian Cai; Juan Xu; Yakun Shao; Jie Gong; Fei Zhao; Lihua He; Xiaoyun Shan
Journal:  J Clin Lab Anal       Date:  2020-02-11       Impact factor: 2.352

Review 7.  Molecular Markers of Antifungal Resistance: Potential Uses in Routine Practice and Future Perspectives.

Authors:  Guillermo Garcia-Effron
Journal:  J Fungi (Basel)       Date:  2021-03-09

8.  Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins.

Authors:  Ainara Hernando-Ortiz; Elena Eraso; Guillermo Quindós; Estibaliz Mateo
Journal:  J Fungi (Basel)       Date:  2021-11-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.